Srivastava, Siddharth
Clark, Bennett
Landy-Schmitt, Colleen
Offermann, Elizabeth A.
Kline, Antonie D.
Wilkinson, Samuel T.
Grados, Marco A.
Funding for this research was provided by:
National Institutes of Health (5K12HS023000)
Article History
First Online: 18 August 2020
Compliance with Ethical Standards
:
: Dr. Wilkinson has received contract funding administered through Yale University from Janssen and Sage Therapeutics for the conduct of clinical trials; he anticipates receiving contract funding from Oui Therapeutics and LivaNova. He has received consulting fees from Janssen, Oui Therapeutics, and Biohaven. Dr. Srivastava has received consulting fees from Guidepoint. The other authors have no other conflict of interest to disclose.
: This was research with human participants, and all participants provided informed consent. Research was approved by the IRB at Johns Hopkins University School of Medicine. We appreciate the help from families and staff of the CdLS Foundation.